Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VERA
stocks logo

VERA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.325
+83.97%
--
--
-1.269
+56.61%
--
--
-1.336
+11.31%
Estimates Revision
The market is revising Downward the revenue expectations for Vera Therapeutics, Inc. (VERA) for FY2026, with the revenue forecasts being adjusted by -5.5% over the past three months. During the same period, the stock price has changed by 76.15%.
Revenue Estimates for FY2026
Revise Downward
down Image
-5.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.27%
In Past 3 Month
Stock Price
Go Up
up Image
+76.15%
In Past 3 Month
Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 68.22 USD with a low forecast of 45.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 68.22 USD with a low forecast of 45.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.610
sliders
Low
45.00
Averages
68.22
High
100.00
Current: 42.610
sliders
Low
45.00
Averages
68.22
High
100.00
JPMorgan
NULL -> Overweight
upgrade
$52 -> $99
2025-12-03
New
Reason
JPMorgan
Price Target
$52 -> $99
2025-12-03
New
upgrade
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Vera Therapeutics to $99 from $52 and keeps an Overweight rating on the shares. The firm is updating its model for Vera following multiple competitive updates for Voyxact (sibeprenlimab) in IgA Nephropathy, the analyst tells investors in a research note. With the evolving market dynamics, particularly total addressable market considerations, the firm sees the product as potentially strategically attractive, JPMorgan added.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$85 -> $90
2025-11-10
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$85 -> $90
2025-11-10
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Vera Therapeutics to $90 from $85 and keeps a Buy rating on the shares after the company presented findings from its ongoing pivotal ORIGIN 3 study with atacicept. The firm projects the drug to generate risk-adjusted revenues of $56M in 2026, growing to $2.5B by 2033.
JPMorgan
Anupam Rama
Overweight
downgrade
$53 -> $52
2025-11-07
Reason
JPMorgan
Anupam Rama
Price Target
$53 -> $52
2025-11-07
downgrade
Overweight
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Vera Therapeutics to $52 from $53 and keeps an Overweight rating on the shares. The firm updated the company's model.
BofA
NULL -> Buy
initiated
$48
2025-10-16
Reason
BofA
Price Target
$48
2025-10-16
initiated
NULL -> Buy
Reason
BofA initiated coverage of Vera Therapeutics with a Buy rating and $48 price target. The firm sees potential upside in shares coming from its lead drug, atacicept, launching into a multibillion-dollar market, the analyst tells investors. The firm notes that its $3B nominal peak sales forecast for 2037 reflects its view that atacicept could offer a favorable treatment option in multiple autoimmune disorders, pending future clinical data validation.
Cantor Fitzgerald
Cantor Fitzgerald
Overweight
maintain
$100
2025-09-18
Reason
Cantor Fitzgerald
Cantor Fitzgerald
Price Target
$100
2025-09-18
maintain
Overweight
Reason
Cantor Fitzgerald keeps an Overweight rating on Vera Therapeutics with a $100 price target after non-profit Kidney Disease: Improving Global Outcomes released updated guidelines for immunoglobulin A nephropathy. The firm sees "direct positive implications" for Vera's atacicept, saying the drug has shown the ability to reduce pathogenic IgA and glomerular injury. Cantor continues to believe the size of the IgA market remains underestimated. Vera in afternoon trading is up 7% to $26.15.
Wolfe Research
Outperform -> Peer Perform
downgrade
2025-08-04
Reason
Wolfe Research
Price Target
2025-08-04
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded Vera Therapeutics to Peer Perform from Outperform without a price target. The firm sees limited near-term upside in the shares given a lack of catalysts, increasing competitive pressure and "fading" takeover prospects. Vera's lead in immunoglobulin A nephropathy is shrinking with the likely November approval of Otsuka's sibeprenlimab, which could be a first-to-market therapy with more convenient dosing, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vera Therapeutics Inc (VERA.O) is -8.13, compared to its 5-year average forward P/E of -7.80. For a more detailed relative valuation and DCF analysis to assess Vera Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.80
Current PE
-8.13
Overvalued PE
-3.55
Undervalued PE
-12.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.01
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.48
Undervalued EV/EBITDA
-9.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.11
Current PS
0.00
Overvalued PS
85.15
Undervalued PS
-50.93
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VERA News & Events

Events Timeline

(ET)
2025-12-02
12:10:00
Vera Therapeutics Shares Rise 19.2% to $39.35
select
2025-11-07 (ET)
2025-11-07
18:30:55
Vera Therapeutics files Biologics License Application for atacicept with the FDA
select
2025-11-06 (ET)
2025-11-06
09:53:12
Vera Therapeutics announces encouraging results from ORIGIN Phase 3 trial of atacicept
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-27TipRanks
Three Stocks Projected to Have Triple-Digit Growth Potential, According to Top Analysts – 11/26/2025
  • Investment Ideas: Top-rated Wall Street analysts recommend several stocks as Buys, indicating potential for significant gains.
  • Research Tool: Investors can explore detailed information about these stocks using TipRanks’ Daily Stock Ratings & Price Targets tool.
[object Object]
Preview
5.0
11-27Newsfilter
Vera Therapeutics Appoints Biopharma Executive Jim Meyers to Board Amid Atacicept Launch Preparations
  • New Board Member: Vera Therapeutics appoints Jim Meyers, a biopharmaceutical executive with over 30 years of commercial leadership experience, to its Board of Directors to support the anticipated launch of the dual BAFF/APRIL inhibitor atacicept, which is expected to transform the treatment of IgA nephropathy and other autoimmune diseases.
  • Strategic Transformation Moment: Meyers joins Vera Therapeutics at a pivotal time as the company focuses on launching atacicept, with plans to rapidly develop this therapy for other diseases, leading to a paradigm shift in autoimmune treatment.
  • Rich Industry Experience: Meyers previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, overseeing market access and pricing in North America and Europe, and his successful track record in launching key products is expected to provide valuable insights for Vera's market strategy.
  • Future Development Potential: Vera Therapeutics is committed to developing atacicept for IgA nephropathy as a once-weekly subcutaneous injection aimed at reducing autoantibodies, which showcases significant potential for changing treatment standards in autoimmune diseases.
[object Object]
Preview
9.5
11-26Benzinga
Nutanix Reports Disappointing Q1 Results, Alongside HP, Ambarella, Pagerduty, and Other Major Stocks Declining in Wednesday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures rose this morning, with Nasdaq futures gaining approximately 50 points on Wednesday.

  • Nutanix Financial Results: Nutanix Inc. shares fell 16.8% in pre-market trading after reporting disappointing first-quarter earnings of 21 cents per share, missing the analyst estimate of 41 cents, and cutting its FY26 sales guidance.

  • Other Stocks Declining: Several other stocks also saw declines in pre-market trading, including Jiayin Group Inc. (-7.8%), Zscaler Inc. (-7.2%), and Workday Inc. (-6.3%), following their respective financial results.

  • Market Reactions: Companies like HP Inc. and Deere & Company also experienced significant drops in share prices after issuing lower-than-expected earnings guidance and financial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vera Therapeutics Inc (VERA) stock price today?

The current price of VERA is 42.61 USD — it has increased 3.27 % in the last trading day.

arrow icon

What is Vera Therapeutics Inc (VERA)'s business?

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

arrow icon

What is the price predicton of VERA Stock?

Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 68.22 USD with a low forecast of 45.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vera Therapeutics Inc (VERA)'s revenue for the last quarter?

Vera Therapeutics Inc revenue for the last quarter amounts to -83.93M USD, increased 68.53 % YoY.

arrow icon

What is Vera Therapeutics Inc (VERA)'s earnings per share (EPS) for the last quarter?

Vera Therapeutics Inc. EPS for the last quarter amounts to -62039000.00 USD, increased 67.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vera Therapeutics Inc (VERA)'s fundamentals?

The market is revising Downward the revenue expectations for Vera Therapeutics, Inc. (VERA) for FY2026, with the revenue forecasts being adjusted by -5.5% over the past three months. During the same period, the stock price has changed by 76.15%.
arrow icon

How many employees does Vera Therapeutics Inc (VERA). have?

Vera Therapeutics Inc (VERA) has 112 emplpoyees as of December 05 2025.

arrow icon

What is Vera Therapeutics Inc (VERA) market cap?

Today VERA has the market capitalization of 2.72B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free